search
Back to results

Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

Primary Purpose

Glioblastoma, Meningeal Arteries

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
interventional procedure to block bilateral meningeal blood supply
Sponsored by
Zhang Nu
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glioblastoma focused on measuring glioblastoma

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Imaging or needle biopsy pathologically diagnosed as glioblastoma Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions There are no related contraindications such as neurovascular intervention and craniotomy Exclusion Criteria: The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma The patient has other underlying medical conditions that affect survival time The patient had other underlying medical conditions that affected follow-up or quality of life assessment Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    interventional procedure to block bilateral meningeal blood supply

    Arm Description

    Outcomes

    Primary Outcome Measures

    Patient survival period
    The overall survival of enrolled patients was compared with the overall survival reported in the literature

    Secondary Outcome Measures

    Postoperative recurring time
    The Postoperative recurring time in enrolled patients was compared with the mean time in the literature

    Full Information

    First Posted
    August 7, 2023
    Last Updated
    August 7, 2023
    Sponsor
    Zhang Nu
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05990556
    Brief Title
    Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
    Official Title
    Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 1, 2023 (Anticipated)
    Primary Completion Date
    September 1, 2025 (Anticipated)
    Study Completion Date
    September 1, 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Zhang Nu

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Glioblastoma is the most common primary malignancy of the central nervous system with a very poor prognosis. Most of the immunotherapies that have made significant breakthroughs in the treatment of other tumors in recent years are unsatisfactory in the application of glioblastoma, which is mainly inseparable from the highly inhibitory immune microenvironment formed by the latter. Therefore, how to change this "immune desert" and better activate immune effector cells to play an anti-tumor effect is currently a hot spot in glioma immune research. In recent years, there has been continuous research support that the myeloid cells of the central nervous system are partly derived from the bone marrow of the skull, and there is a special channel connection between the skull and the dura mater, through which immune cells can be transported. This suggests that some of the tumor-associated macrophages recruited in the glioblastoma microenvironment may be passed through the dura mater. In previous animal experiments, we blocked the main blood supply to the dura mater by ligating the bilateral external carotid arteries of mice, cutting off the potential supply of dura mater to suppressor myeloid cells in the lesion. The results showed that after ligation of bilateral external carotid arteries, the survival period of tumor-forming mice was significantly prolonged and the prognosis was improved. The proportion of myeloid cells in the tumor microenvironment of mice decreased significantly, and the expression of tumor suppressor molecules such as arginase Arg1 decreased, indicating that the improvement of mouse prognosis was closely related to the proportion and phenotypic changes of myeloid cells after dural blood supply blockade. The meningeal lymphatic system of the human central nervous system has been shown to be an important part of the immune system, while the external carotid artery system, the main source of blood supply to the dura, carries abundant immune cells that ooze out to the dura mater through the endothelial window hole of the dural blood vessel, which is an important source of dural immune cells. In the glioblastoma immune microenvironment, the source of immune cells includes dural branches from the external carotid artery system in addition to branches of the internal carotid artery system. Therefore, for patients diagnosed with glioblastoma, this study involves embolization of the dural branch of the external carotid artery system (bilateral middle meningeal artery) to block the dural blood supply before craniotomy. At the same time, microsurgery under multimodal image navigation was used to remove the tumor. It is expected to be effective in reducing the proportion of myeloid suppressor cells in the tumor microenvironment, slowing the growth rate of residual tumor cells, and prolonging the tumor-free progression and survival of patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Glioblastoma, Meningeal Arteries
    Keywords
    glioblastoma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    Interventional single-arm studies, no grouping. 1 Randomize groupings 1.1 Method for generating random sequence assignments This study is a real-world study, it is planned to include 20 patients as a case, there is no need for random sequence and blinded allocation before intervention, the patient's condition, experimental purpose, experimental method and possible risks are informed before surgery, and the patient chooses whether to undergo preoperative interventional surgery to block bilateral meningeal blood supply. 1.2 Randomly assigned hiding This is a real-world study that intends to include three patients as individual cases without random sequencing prior to intervention and therefore does not involve allocation concealment.
    Masking
    None (Open Label)
    Masking Description
    Blinding and unblinding This is a real-world study that intends to include three patients as case studies without blinding prior to intervention and therefore does not involve blinding.
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    interventional procedure to block bilateral meningeal blood supply
    Arm Type
    Experimental
    Intervention Type
    Procedure
    Intervention Name(s)
    interventional procedure to block bilateral meningeal blood supply
    Intervention Description
    The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue ("liquid embolic system"). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging.
    Primary Outcome Measure Information:
    Title
    Patient survival period
    Description
    The overall survival of enrolled patients was compared with the overall survival reported in the literature
    Time Frame
    15 months
    Secondary Outcome Measure Information:
    Title
    Postoperative recurring time
    Description
    The Postoperative recurring time in enrolled patients was compared with the mean time in the literature
    Time Frame
    3-6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Imaging or needle biopsy pathologically diagnosed as glioblastoma Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions There are no related contraindications such as neurovascular intervention and craniotomy Exclusion Criteria: The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma The patient has other underlying medical conditions that affect survival time The patient had other underlying medical conditions that affected follow-up or quality of life assessment Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nu Zhang, Professor
    Phone
    13825070717
    Email
    zhangnu2@mail.sysu.edu.cn
    First Name & Middle Initial & Last Name or Official Title & Degree
    Kejun He, Attending
    Phone
    15920463410
    Email
    mailto:hekejun3@ms.sysu.edu.cn
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nu Zhang, Professor
    Organizational Affiliation
    First Affiliated Hospital, Sun Yat-Sen University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

    We'll reach out to this number within 24 hrs